Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

INTRODUCTION: Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the respective vaccines continues to increase, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugh, Sarah, Wasserman, Matt, Moffatt, Margaret, Marques, Susana, Reyes, Juan Manuel, Prieto, Victor A., Reijnders, Davy, Rozenbaum, Mark H., Laine, Juha, Åhman, Heidi, Farkouh, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237584/
https://www.ncbi.nlm.nih.gov/pubmed/32096144
http://dx.doi.org/10.1007/s40121-020-00287-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237584/
https://www.ncbi.nlm.nih.gov/pubmed/32096144
http://dx.doi.org/10.1007/s40121-020-00287-5

Ejemplares similares